Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 439-445

  Galmarini, Carlos María ^a   Clarke, Marilyn L ^b   Falette, Nicole ^a   Puisieux, Alain ^a   Mackey, John R ^b   Dumontet, Charles ^a  

^a INSERM   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antimetabolites; Apoptosis; Cell death; Drug resistance; Gemcitabine; Protein p53

Indexed keywords

AMECYTINE; DOXORUBICIN; GEMCITABINE; MITOMYCIN C; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL KINETICS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036466841     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1628     Document Type: Article

References (41)

1. Phase I trial of gemcitabine (Gemzar), 24 hr infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
2. Gemcitabine in advanced breast cancer
3. Chemotherapy for advanced non-small cell lung cancer: Past, present and future
4. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1
5. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
6. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase
7. Preclinical characteristics of gemcitabine
8. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine
9. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity
10. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
11. Gemcitabine: Metabolism, mechanisms of action and self-potentiation
12. Induction of apoptosis by gemcitabine
13. 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
14. The role of nucleoside transport in anticancer drug resistance
15. Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780
16. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukemic line K562
17. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2′,2′-difluorodeoxycytidine in the human KB cancer cell line
18. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization
19. Modulation of drug cytotoxicity by reintroduction of wildtype p53 gene (Ad5CMV-p53) in human pancreatic cancer
20. Cancer: p53, guardian of the genome
21. p53, cell cycle control and apoptosis: Implications for cancer
22. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells
23. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
24. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
25. p53 status and the efficacy of cancer therapy in vivo
26. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding
27. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562
28. Chemosensitivity testing of fresh leukemia cells using the MTT colorimetric assay
29. Separation of 1-beta-D-arabino-furanosylcytosine 5′-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography
30. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
31. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage
32. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs
33. Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, Bcl-2 and dexamethasone
34. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
35. Bcl-2 and the regulation of programmed cell death
36. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis
37. Bim: A novel member of the Bcl-2 family that promotes apoptosis
38. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells
39. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
40. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system
41. Cisplatin and gemcitabine in non-small-cell lung cancer